Secondary Logo


     Leukemia​          Lymphoma         Multiple Myeloma​

Online Extra

CML.jpeg Discussion on the Role of Immunotherapy in ALL

There has been significant success in the treatment of pediatric acute lymphoblastic leukemia patients, however the same cannot be said about the adult population. Why is this the case?​


Researchers Launch Screening Study of Individuals at High Risk of Multiple Myeloma

Researchers at Dana-Farber Cancer Institute have launched the PROMISE study, which will help scientists track the molecular changes that occur as precursor conditions progress to myeloma

FDA Alert


NEW APPROVAL: Ibrutinib Plus Obinutuzumab Accepted for Priority Review in CLL/SLL

If the sNDA is approved, the use of ibrutinib with obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for the first-line treatment of CLL/SLL

Your Career Path


Putting Physician Burnout Under the Microscope

How can hematologist/oncologists make a difference when it comes to combatting physician burnout?


Featured Articles

CML.jpegImmunotherapy Shows Promise in Treatment of Hodgkin Lymphoma​

By Catlin Nalley

Immunotherapy continues to gain momentum across a multitude of cancer types and lymphoma is no exception.​


ASCO Names CAR T-Cell Immunotherapy 2018 Advance of the Year

By Peggy Eastman

The FDA approved CAR T-cell therapy in 2017 to treat adults with DLBCL, as well as children and young adults with ALL.​


Applying Genomics to Leukemias & Lymphomas

By Ankur R. Parikh, DO

Utilization of next-generation sequencing in clinical hematologic oncology practice is rapidly rising.​

From the Issue


Genetic Subtyping of Diffuse Large B-Cell Lymphomas

By Richard Simoneaux

Diffuse large B-cell lymphomas are a genetically diverse group of diseases that constitute the largest group of non-Hodgkin lymphomas.

The Medicine, Miracles & Masterminds Behind CAR T-Cell Therapy​

By Valerie Neff Newitt

Take a closer look at the emergence of CAR T-cell therapy and hear from the masterminds behind this revolutionary approach, including Carl June, MD, and Steven A. Rosenberg, MD, PhD​.

From the Experts

10 Steps to Improve Grand Rounds

Carlos de Castro, MD, Professor in Medicine at Duke University Medical Center Division of Hematologic Malignancies & Cellular Therapy, shares his expertise to help you conduct successful grand rounds with your team.

Research Minute

Q&A on Chronic Lymphocytic Leukemia​

Clive Zent, MD, discusses his recent research, which is featured in the September 20 issue of HemOnc Times. 


Clinical Trials of Interest 

Pierluigi Porcu, MD, of Sidney Kimmel Cancer Center at Jefferson Health, discusses a few hematology/oncology clinical trials in which he and his team are involved.